Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer

  • Sebio, Ana|||0000-0003-3333-2370
  • Matsusaka, Satoshi
  • Zhang, Wu
  • Yang, Dongyun
  • Ning, Yan
  • Stremitzer, Stefan
  • Stintzing, Sebastian
  • Sunakawa, Yu
  • Yamauchi, Shinichi
  • Fujimoto, Yoshiya
  • Ueno, Masaki
  • Lenz, Heinz-Josef
The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil. In this study 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. Patients with a RASSF1A rs2236947 AA genotype had higher 3-year recurrence rate than patients with CA/CC genotypes (56% vs 33%, HR: 1.87; p =0.017). Patients with TAZ rs3811715 CT or TT genotypes had lower 3-year recurrence rate than patients with a CC genotype (28% vs 40%; HR: 0.66; p =0.07). In left-sided tumors, this association was stronger (HR: 0.29; p =0.011) and a similar trend was found in an independent Japanese cohort. These promising results reveal polymorphisms in the Hippo pathway as biomarkers for stage II and III colon cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy, results from FIRE-3 and JACCRO 05 and 06 trials

  • Sebio, A.
  • Stintzing, Sebastian
  • Heinemann, V.
  • Sunakawa, Yu
  • Zhang, W.
  • Ichikawa, W.
  • Tsuji, A.
  • Takahashi, T.
  • Parek, A.
  • Yang, Dawei
  • Cao, S.
  • Ning, Y.
  • Stremitzer, Stefan
  • Matsusaka, Satoshi
  • Okazaki, S.
  • Barzi, A.
  • Berger, M.
  • Lenz, H-J
The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. Two cohorts treated with cetuximab plus chemotherapy were evaluated (198 RAS wild-type (wt) patients treated with first-line FOLFIRI plus Cetuximab within the FIRE-3 trial and 67 Ras wt patients treated either with first-line mFOLFOX6 or SOX plus Cetuximab). In these two populations, Rassf1a rs2236947 was associated with overall survival, as patients with a CC genotype had significantly longer OS compared to those with CA or AA genotypes. This association was stronger in patients with left-side CRC [HR: 1.79 (1.01-3.14); P =0.044 and HR: 2.83 (1.14-7.03); P =0.025, for Fire 3 and JACCRO cohorts, respectively]. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.